Sunshine Biopharma Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 |
| Cost of revenue | $24.1M | $24.2M | $15.8M | $2.6M | $117,830 |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110,596 |
| Research and development | $604,308 | $933,902 | $1.9M | $811,858 | $672,209 |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M |
| Interest expense | $0 | $8,774 | $137,308 | $39,412 | $328,818 |
| Pretax income | -$6.0M | -$5.4M | -$4.1M | -$26.5M | -$12.4M |
| Income tax expense | $21,609 | -$234,858 | $395,166 | $233,304 | $0 |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M |
| Balance Sheet | |||||
| Cash and equivalents | — | — | — | $21.8M | $2.0M |
| Current assets | $26.9M | $26.0M | $24.9M | $27.3M | $2.2M |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M |
| Current liabilities | $6.4M | $6.3M | $5.6M | $6.9M | $91,229 |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M |
| Stockholders' equity | $23.0M | $23.5M | $21.2M | $21.6M | $211,662 |
| Cash Flow Statement | |||||
| Cash from operations | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M |
| Depreciation and amortization | $332,070 | $223,527 | $149,147 | $20,641 | $12,741 |
| Capital expenditure | $174,491 | $1.7M | $82,251 | $193,982 | $0 |
| Free cash flow | -$5.5M | -$14.2M | -$8.9M | -$5.4M | -$1.8M |
| Share repurchases | $0 | $3.1M | $541,143 | — | — |
| Impairments | — | — | $0 | $18.3M | $0 |
Shares outstanding 5.0M · Free float 23.5%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.